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Objective: Gene transfer to lung grafts may be useful in ameliorating 
ischemia-reperfusion injury and rejection. Efficient gene transfection tothe 
whole organ may prove problematic. Proximal pulmonary artery endothe- 
lial transfection might provide beneficial downstream effects on the whole 
graft. The aim of this study was to determine the feasibility of transfecting 
proximal pulmonary artery segments in lung isografts. Methods: Male 
Fischer rats were divided into six groups. In vivo transfection: In group I 
(n = 7), a proximal segment of the left pulmonary artery was isolated and 
injected with saline solution by means of a catheter inserted through the 
right ventricle. After an exposure period of 20 minutes, clamps were 
removed and blood flow was restored. In group II (n = 7), the isolated 
arterial segments were injected with adenovirus carrying the Escherichia 
coli LacZ gene encoding for ~-galactosidase. Ex vivo transfection: In group 
III (n = 5), arterial segments were injected ex vivo with saline solution and 
in group IV (n = 5) with the adenovirus construct. In group V (n = 6), 
arteries were injected with saline solution and in group VI (n = 11) with 
liposome chloramphenicol acetyl transferase cDNA. In groups I to IV, 
animals were killed on postoperative day 3 and transgene xpression was 
assessed by Bluo-Gal staining. In groups V and VI, animals were killed on 
postoperative day 2 and transgene xpression was assessed by chloram- 
phenicol acetyl transferase activity assay. Results: Transgene xpression 
was detected grossly and microscopically in endothelial nd smooth muscle 
cells of pulmonary artery segments from all surviving animals of groups II 
and IV. In group VI, chloramphenicol acetyl transferase activity was significant 
in all assessed arterial segments. Conclusion: Significant transgene expression 
is observed in proximal pulmonary artery segments after both in vivo and ex 
vivo exposure. (J Thorac Cardiovasc Surg 1997;114:793-802) 
R ecent advances in gene therapy techniques have made possible the introduction of recombinant 
genes into mammalian somatic cells, opening the 
possibility of treating inherited and acquired dis- 
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eases at the genetic level. Currently, 107 human 
gene transfer clinical trials have been approved by 
the Recombinant DNA Advisory Committee of the 
National Institutes of Health)  
Gene therapy has been tested in various trans- 
plant systems: heart, 2 liver, ~ and kidney. 4 Recently, 
we 5 have demonstrated ex vivo gene transfer to 
whole lung isografts using an adenoviral vector. 
However, transgene xpression was patchy and un- 
predictable. One possible explanation for this pat- 
tern of transgene xpression is the huge surface area 
of the pulmonary microvasculature, which would 
alter the adenovirus/host cell ratio, an important 
factor for  transduction efficiency. Thus we hypothe- 
sized that gene transfer to the proximal segment of 
the pulmonary artery could avoid this variable and 
allow a downstream beneficial effect to the whole 
graft. The purpose of the present study was to 
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Table I. Total ischemic time and survival 
Survival 
Total ischemic time 
Group (min) Alive~total (%) 
5/7 71.4 I 27.1 -+ 1.0 NS 
II 28.9 -+ 0.5 3/7 42.9 
5/5 100.0 III 177.6 +- 4.6 NS 
IV 193.4 -+ 7.1 5/5 100.0 
5/6 83.3 V 97.9 -+ 5.6 NS 
VI 110.0 -+ 3.7 9/11 81.8 
NS, Not significant. 
demonstrate the feasibility of gene transfer to pul- 
monary artery segments using both adenoviral and 
liposomal vectors. 
Materials and methods 
Adenoviral vector. First-generation replication-defi- 
cient adenovirus erotype 5 carrying the Escherichia cog 
LacZ gene encoding for/3-galactosidase and driven by the 
constitutive cytomegalovirus promoter (Ad5.CMV./3-gal) 
was used. The LacZ gene was chosen because/3-galacto- 
sidase activity is easily measured in situ with reliable and 
sensitive histochemical ssays that use chromogenic sub- 
strates. Ad5.CMV./3-gal, provided by Dr. Allan Schwartz 
(Children's Hospital, St. Louis, Mo.), was grown in the 
human embryonic kidney 293 cell line (American Type 
Culture Collection, Rockville, Md.). The virus was puri- 
fied and the number of viral particles was assessed on the 
basis of the optical density at 260 nm (1 OD26 o = 5 × 10 ix 
particles per milliliter). Purified virus aliquots were stored 
at -80°C in a buffered solution of 10% glycerol, 1 × 
TD*/1 mmol/L MgC12. The viability of adenoviral prepa- 
rations was assayed by adenoviral transduction of293 cells 
plated in six-well plates, using limiting dilution of adeno- 
3 12 virus (10- to 10- ) followed by in situ Bluo-Gal staining 
12 hours later. After an 18-hour staining period at 37 ° C, 
plates were examined with a light microscope for the 
presence of blue-stained cells, corresponding to trans- 
duced cells producing /3-galactosidase. In the present 
study, the concentration of adenoviral vectors adminis- 
tered was 2 to 4 × 1012 viral particles per milliliter. 
Cationic lipid. The plasmid pCF1-CAT (Genzyme 
Corporation, Framingham, Mass.) consists of the human 
cytomegalovirus immediate early gene promoter/en- 
hancer, a hybrid intron, the chloramphenicol acetyl trans- 
ferase (CAT) cDNA, the bovine growth hormone polyad- 
enylation signal sequence, and the kanamycin resistance 
gene, as previously described. 6 Lipid 67 (Genzyme Cor- 
poration) is an amphiphile consisting of a hydrophobic 
cholesterol lipid anchor linked to a spermine head group 
in a T-shape configuration and was used in a 1:2 molar 
ratio. Before use, dried lipid films were hydrated with 
sterile water, treated in a vortex, placed on ice for 10 
minutes, then placed in a vortex again. Equal volumes of 
lipid 67/DOPE (L-dioleoyl phosphatidyl-ethanolamine) 
*Tris dialysis buffer: 137 mmol/L NaC1; 5 mmol/L KC1; 25 
mmol/L Tris; 0.7 mmol/L Na2HPO 4. 
and plasmid DNA were mixed and incubated at room 
temperature for 30 minutes. Final concentrations were 1 
mmol/L cationic lipid and 4 mmol/L plasmid DNA. 
Animals. Inbred male F344 rats (Harlan Sprague Daw- 
ley Inc., Indianapolis, Ind.), weighing 250 to 290 gm, were 
used in all experiments. All animal procedures were 
approved by the Animal Studies Committee at Washing- 
ton University. Animals received humane care in compli- 
ance with "Principles of Laboratory Animal Care" formu- 
lated by the National Society for Medical Research and 
the "Guide for the Care and Use of Laboratory Animals" 
prepared by the National Academy of Sciences and pub- 
lished by the National Institutes of Health (NIH publica- 
tion 85-23, revised 1985). 
In vivo gene transfer to pulmonary artery segments. 
Animals were divided into groups I (n = 7) and II (n = 7). 
All animals were anesthetized with an intramuscular 
injection of ketamine (30 mg/kg) and atropine sulfate 
(0.15 mg/kg). After intubation, the lungs of all animals 
were ventilated mechanically (model 683, Harvard Appa- 
ratus, Inc., South Natick, Mass.) (tidal volume 10 ml/kg, 
respiratory rate 60 breaths/min, positive end-expiratory 
pressure 1.0 cm H20), and anesthesia was maintained 
with 0.5% halothane. A left thoracotomy was performed 
through the third intercostal space. The left pulmonary 
artery was isolated from the hilum to the pulmonary trunk 
after excision of the left superior vena cava. A 24-gauge 
polyethylene catheter was inserted from the right ventricle 
into the left pulmonary artery, which was then ligated 
distally. The proximal end of the left pulmonary artery was 
ligated over the catheter just distal to the main pulmonary 
artery bifurcation, and blood was aspirated from the 
occluded segment of left pulmonary artery. In group I, 
0.03 ml of 0.9% saline solution was injected into the 
isolated arterial segments. In group II, the arterial seg- 
ment received 0.03 ml of the adenoviral solution (6 to 
12 × 10 l° vital particles). The catheter was removed 
immediately after injection, and right ventricular bleeding 
was controlled with compression. The isolated segment of 
pulmonary artery was distended by the injection and 
maintained this appearance during the 20-minute xpo- 
sure period. This 20-minute xposure period was judged 
to be an acceptable period of warm ischemia. After this 
exposure period, clamps were removed and blood flow 
restored to the left lung. A thoracic tube was placed and 
the thorax closed. After spontaneous breathing resumed 
and the animal recovered from anesthesia, the thoracic 
tube and endotracheal tube were removed. 
Ex vivo gene transfer to pulmonary artery segments. 
Orthotopic left lung transplantation was performed by 
means of a modification of the previously described "cuff 
technique.,,7, s With anesthesia, mechanical ventilation, 
and systemic heparinization, donor rat lungs were flushed 
through the main pulmonary artery with 20 ml of cold 
(4°C) low-potassium dextran/l% glucose solution in 
groups III and IV. In groups V and VI, lungs were flushed 
with saline solution to avoid precipitation of cationic lipid. 
Heart-lung blocks were extracted and, with the use of the 
same procedure as in the in vivo study, 0.03 ml of saline 
solution in group III (n = 5), 0.03 ml of adenoviral 
lo solution (6 to 12 × 10 viral particles) in group IV (n = 
5), 0.03 ml of saline solution in group V (n = 6), and 0.03 
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Fig. 1. Recombinant gene expression with Bluo-Gal staining on the endothelial surface. In vivo transfec- 
tion (group II) (A) and ex vivo transfection (group IV) (B) are seen with blue spots through the microscope 
(original magnification ×100). 
ml of cationic lipid in group IV (n = 11) was injected into 
the isolated left pulmonary artery segments. After injec- 
tion, lung grafts in groups III and IV were stored for 2 
hours in 10°C low-potassium dextran/glucose olution. 
This exposure time and temperature were selected be- 
cause our previous tudies indicated that subsequent graft 
function would be acceptable and transgene xpression 
would be achieved. The lung grafts in groups V and VI 
were stored for i hour in room temperature (23 ° C) saline 
solution. Room temperature was selected to avoid precip- 
itation of cationic lipid. This 1-hour exposure period was 
set to avoid severe warm ischemia-reperfusion njury and 
to obtain efficient recombinant gene expression. Subse- 
quently the ligature and distal clamp were removed from 
the pulmonary artery. A 14-gauge polyethylene catheter 
cuff was attached to the proximal stump of the pulmonary 
artery, vein, and left bronchus. The donor left lung graft 
was implanted. 
Bluo-Gal staining. All surviving animals in groups I to 
IV were killed 72 hours after reperfusion. Recombinant 
gene expression appeared 48 to 72 hours after expo- 
sure.9, lo The native right and transplanted left lungs were 
harvested and stained with Bluo-Gal solution. Harvested 
heart-lung blocks were flushed through the pulmonary 
arterial trunk with 20 ml of phosphate-buffered saline 
solution (PBS), 20 ml of 2% paraformaldehyde solution 
with added 0.2% glutaraldehyde, and 0.02% nonionic 
detergent (Nonidet P-40 [octylphenol-ethylene oxide]) 
and stored in 2% paraformaldehyde solution for 20 min- 
utes. After that, lungs were flushed with 20 ml of PBS, 
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Fig. 2. Recombinant gene expression with Bluo-Gal staining on the pathologic specimens of a pulmonary 
artery segment. In vivo transfection (group II) (A) and ex vivo transfection (group IV) (B) are seenwith 
blue spots on the endothelial cells and smooth muscle cells stained with nuclear fast red stain (original 
magnification ×400). 
followed by a flush of 10 ml of Bluo-Gal, and finally were 
immersed in Bluo-Gal buffer for 3 hours at 37 ° C. The 
Bluo-Gal buffer was prepared by mixing 1 mg/ml Bluo-Gal 
(5-bromo-indolyl-/3-o-galactopyranoside; Gibco BRL, 
Gaithersburg, Md.), 5 mmol/L K3FelII(CN)6, 5 mmol/L 
K4Fe II (CN)6 , 2 mmol/L MgC12, 0.1% Nonidet P-40, and 
PBS. After another flushing with 20 ml PBS, lungs were 
fixed with 4% paraformaldehyde. Histologic sections were 
stained with nuclear fast red dye. 
CAT activity assay. All survival animals in groups V 
(n = 5) and VI (n = 9) were killed 48 hours after 
reperfusion. In all surviving animals in group V and five 
animals in group VI, CAT activity was assessed. Trans- 
gene expression was detected by a CAT activity assay as 
described elsewhere. 11In brief, after tissue homogeniza- 
tion and dilution in tromethamine-ethylenediaminetet- 
raacetic acid, three consecutive freeze/thaw cycles were 
performed. After incubation at 65 ° C, samples were cen- 
trifuged at 10,000 rpm; then the supernatant was recov- 
ered and a quantitative spectrophotometric analysis was 
performed. Protein extract, 300 /xg, was incubated over- 
night at 37 ° C with 40 ~1 of acetyl coenzyme A and 8/xl of 
14C chloramphenicol; then ethyl acetate was added. The 
samples were placed in a vortex, centrifuged at 14,000 
rpm, and the supernatant was recovered. This was nitro- 
gen-dried and then resuspended in ethyl acetate. Thin- 
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Group V { control ) Group VI ( Lipid ) 
Fig. 3. CAT activity in groups V and VI. In the lipid group (VI), strong and consistent expression 
of CAT is apparent, di-AC, Diaceylated; mono-AC, monoaceylated; non-AC, nonaceylated. 
layer chromatography was followed by overnight autora- 
diography. In the presence of functional CAT enzyme, 
both monoaceylated and diacetylated forms of chloram- 
phenicol are produced, which are distinct from the non- 
acetylated chloramphenicol by thin-layer chromatogra- 
phy. 
In situ hybridization, In remaining survival animals 
(n = 4) in group VI, in situ hybridization was performed 
with sense and antisense 3SS-radiolabeled cRNA for CAT 
as previously described. 12 In brief, 35S-labeled RNA 
probes were transcribed in vitro from cDNA probes for 
the CAT gene with the use of 3SS-uridine triphosphate. 
Sections of paraffin-embedded lung tissue were pretreated 
with nuclease-free proteinase K and washed in triethanol- 
amine buffer containing 0.25% acetic anhydride. Hybrid- 
ization solution containing 2.5 × 105 cpm of 35S-labeled 
probes was added and incubated with RNase and incu- 
bated overnight. This was washed extensively under strin- 
gent conditions and then incubated with RNase A to 
remove unhybridized probe. Washed slides then were 
processed by autoradiography. 
Graft function. In groups III to VI, the right (contralat- 
eral) hilum was clamped immediately before the animal 
was killed. Isolated function of the left lung isograft was 
assessed by arterial blood gas analysis during mechanical 
ventilation with 100% oxygen (tidal volume 1.5 ml, respi- 
ratory rate 100/min, positive end-expiratory pressure 1.0 
cm H20 ). 
Histology of graft lungs. In all surviving animals of 
groups I to IV, after fixation with 2% paraformaldehyde 
solution, histologic sections of lung grafts were stained 
with hematoxylin and eosin in addition to nuclear fast red 
stain. In all surviving animals of groups V and VI, lung 
grafts were fixed with 10% formalin and stained with 
hematoxylin and eosin. 
Statistical analysis. All values are presented as the 
mean -+ standard error of the mean. Unpaired two-group 
t test and Mann-Whitney test were used to compare 
differences of total ischemic time and arterial oxygen 
tension between corresponding groups. Differences were 
considered significant when p < 0.05. 
Results 
The ischemic times and survivals for each group 
are shown in Table I. There were no significant 
differences between control groups and correspond- 
ing transfection groups. Five of seven animals in 
group I and three of seven animals in group II 
survived until they were killed at 72 hours. In groups 
I I I  and IV, all animals survived 72 hours. Five of six 
animals in group V and nine of 11 animals in group 
VI survived for assessment a 48 hours. 
Recombinant gene expression. All surviving ani- 
mals in group II and all animals in group IV showed 
multiple blue spots on the endothelial surface of the 
left pulmonary artery as recombinant gene expres- 
sion (Fig. 1). No blue spots appeared on the endo- 
thelial surface of the contralateral right pulmonary 
artery in groups II and IV. In groups I and III, blue 
spots did not appear on the endothelial surface of 
either pulmonary artery. 
Microscopically, transgene expression was ob- 
served as the blue granular spots in groups II and IV 
in endothelial cells and smooth muscle cells located 
near the lumen (Fig. 2). Transgene xpression was 
not observed in either lung or the right pulmonary 
artery in any of the groups. 
CAT activity. In all five group VI animals, trans- 
gene expression was detected in pulmonary artery 
segments ubmitted for CAT activity assay. Each 
pulmonary artery segment showed high levels of 
CAT activity (Fig. 3). The intensity of CAT activity 
was similar in all animals. 
In situ hybridization. In the four group VI ani- 
mals, pulmonary artery segments were submitted for 
in situ hybridization. CAT gene was detected with 
concentration of positive signals around endothelial 
cells (Fig. 4). 
Arterial blood gas analysis. Mean arterial oxygen 
tension in groups I I I  to VI is shown in Fig. 5. There 
were no significant differences between groups I I I  
and IV (348.1 _+ 78.3 vs 367.6 _+ 85.9 mm Hg) and 
between groups V and VI (317.1 _+ 45.2 vs 266.0 + 
69.2 mm Hg). 
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Fig. 4. In situ hybridization in group VI. CAT gene was detected with concentration f positive signals 
around endothelial cells using both bright-field microscopy (A) and dark-field microscopy with reflected 
polarized light (B) (original magnifications ×200). 
Histology. In groups I and II, histologic speci- 
mens of the lung graft showed severe edema of 
alveolar wall and neutrophil infiltration. Similar 
infiltration was seen in specimens of groups V and 
VI. The infiltration in groups III and IV was much 
less significant han in other groups. There were 
no significant differences between control groups 
and corresponding transfection groups in the 
pathologic specimens of the lungs and pulmonary 
arteries. 
Discussion 
Ischemia-reperfusion njury and rejection remain 
major obstacles to successful transplantation. 13 
Gene transfer to the lung graft has the potential to 
reduce these major problems. We 5 have previously 
demonstrated whole lung graft transduction using 
an adenoviral vector. However, the method was 
inefficient. 
Transfection of a proximal segment of the pulmo- 
nary artery offers certain advantages. First, in the in 
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vivo setting, it is possible to confine the vector-DNA 
complexes to the isolated arterial segments and not 
expose other organs to a gene that is not necessary. 
In addition, in cases of functional gene transfection, 
the secreted protein may have beneficial down- 
stream effects to the whole graft. Finally, with high 
construct to endothelial cell ratios and ideal storage 
times, transgene expression efficiency might be max- 
imized. 
In the present study, we tested both adenoviral 
and liposomal vectors. Adenoviral vectors have 
some advantages. 1'14 They can accept relatively 
large pieces of exogenous DNA and do not require 
replicating cells to introduce their recombinant gene 
as retroviruses. Furthermore, they can be rendered 
replication defective by deletion of the E1 genomic 
region and can be produced at high titers. Never- 
theless, vital vectors can trigger a host immune- 
inflammatory esponse, thereby limiting their utility. 
Using second-generation adenovirus vectors from 
which the E1 and E4 genomic regions have been 
deleted minimizes their pathogenicity. ~5 Liposomes 
have been regarded as less efficient delivery systems. 
Despite this perception, we ~6 have recently demon- 
strated consistent and reproducible transgene x- 
pression when a liposomal vector was used to trans- 
fect whole lung grafts in vivo and ex vivo. In 
addition, liposomes, unlike vital vectors, have no 
replication risk and do not activate the host im- 
mune-inflammatory response, as occurs with viral 
vectors. 
In vivo adenovirus-mediated g ne transfer to seg- 
ments of pulmonary arteries was achieved in all 
animals that survived the operative-transfection 
procedure. However, the survivals of groups I and II 
were unexpectedly low. These could be explained by 
the warm ischemic injury to which lungs were sub- 
jected when the arterial segments were isolated for 
about 30 minutes. Also, bleeding from the insertion 
point of the right ventricular catheter might have 
contributed to the high mortality in these groups. 
Histologically, lungs in these groups showed severe 
edema in the alveolar wall and leukocyte infiltration 
into alveolar spaces characteristic of reperfusion 
injury. There were no histologic differences between 
the adenoviral transduced group and the control 
group that received only saline solution. 
In the ex vivo adenovirus-mediated g ne transfer 
group, recombinant gene expression was detected in
all cases. The were no deaths. The ex vivo approach 
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Fig. 5. Arterial oxygen tension in groups III to VI. There 
are no differences between corresponding groups. NS, Not 
significant. 
such as temperature and exposure time. In these 
experiments the cold storage time was 2 hours. 
Nonetheless, there was no severe ischemia-reperfu- 
sion injury as was observed in the in vivo group. 
Arterial oxygenation levels were high in the ex vivo 
group. There were no differences between adenovi- 
ral transduced grafts and controls with respect to gas 
exchange or histologic appearance. 
In lungs transduced with the adenoviral vector 
(groups II and IV), recombinant gene expression 
was assessed by Bluo-Gal staining. Bluo-Gal was 
selected because it is more stable than X-Gal (5- 
bromo-4-chloro-3-indolyl-d-galactosidase) in that 
the blue color of transduced cells does not fade 
during the staining process of paraffin-embedded 
histologic sections. 17 Many blue spots were observed 
on the endothelial surface of the pulmonary artery 
segments. Histologically, transgene xpression was 
detected in endothelial and smooth muscle cells 
located near the endothelial layer, demonstrating 
that the adenovirus could traverse the endothelium 
and transduce the smooth muscle cells. However, in 
comparison with the gross appearance of the endo- 
thelial surface before histologic preparation, the 
blue spots seemed to decrease. It is possible that 
during the histologic staining process some spots 
faded. Although recombinant gene expression was 
easily assessed by Bluo-Gal staining, the staining 
was heterogeneous even in this study, and gene 
expression was not quantified. It is possible to count 
the stained cells microscopically per high-power 
field, but the number of blue-stained cells did not 
correspond to what was observed grossly. 
800 Yano et aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
November 1997 
Although it is difficult to compare in vivo and ex 
vivo studies, 20 minutes' incubation at body temper- 
ature in vivo nearly equaled 2 hours of ex vivo 
incubation at 10 ° C. The low temperature (10 ° C) 
did not seem to have much effect on adenoviral 
infectivity. 
In the ex vivo liposome-mediated gene transfer 
group (group VI), significant and consistent recom- 
binant gene expression was observed in all arterial 
segments assessed by either thin-layer chromatogra- 
phy or in situ hybridization. In this group, transfec- 
tion was processed at room temperature to avoid 
precipitation of liposome. Histologically, the left 
lungs of groups V and VI showed severe neutrophil 
infiltration, perhaps because of the increased stor- 
age temperature (23 ° C). In the histologic sections 
assessed by in situ hybridization, many endothelial 
cells have been peeled off. It is difficult to define 
which process caused that. However, it might con- 
cern room temperature storage. 
In the present study, complete segmental occlu- 
sion was possible in the in vivo and ex vivo studies. 
The pulmonary arteries easily expanded. This pres- 
sure seemed to result in satisfactory transfection 
even to smooth muscle cells. Inasmuch as the pul- 
monary artery endothelium is surrounded by a thick 
smooth muscle layer, leakage of the adenoviral 
vector to the systemic or lymphatic irculation does 
not seem to occur, contrary to what has been 
demonstrated when the adenoviral vector is infused 
into the pulmonary microvasculature. 5 
Our ultimate goal is to use gene therapy to target 
two important problems that occur after lung trans- 
plantation: ischemia-reperfusion injury and rejec- 
tion. Gene transfer with plasmid DNA encoding 
transforming rowth factor-/31 prolonged allograft 
survival in a mouse cardiac transplantation model, as 
Alloreactivity has been suppressed with adenovirus- 
mediated gene transfer expressing viral interleu- 
kin-10 using an in vivo rat liver transplantation 
model. 19 In vitro, retrovirus-mediated superoxide 
dismutase cDNA transfer has been reported to 
prevent ischemia-reperfusion njury. 2° Likewise, in- 
ducible nitric oxide synthase gene transfer is possi- 
ble 21 and may improve graft function, as we have 
previously demonstrated the effects of inhaled nitric 
oxide 22'23 and nitroprusside 24 after canine lung 
transplantation. Gene transfer to segments of pul- 
monary artery by means of functional genes may be 
useful in reducing ischemia-reperfusion injury and 
rejection. 
In conclusion, we have demonstrated the feasibil- 
ity of successful gene transfer to rat pulmonary 
arterial segments in vivo and ex vivo. 
We thank Allan Schwartz, MD, Jia-J. Hui, MD, Kath- 
leen Grapperhaus, Mathew Bernstein, and Wei Zhang for 
technical assistance and Dawn Schuessler for secretarial 
support. 
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Discussion 
Dr. Larry R. Kaiser (Philadelphia. Pa.). Do you have an 
idea of the multiplicity of infection that you would have 
used with your adenoviral construct? It looked like a fairly 
high dose of adenovirus. Also. did you look at different 
doses of adenovirus to see whether you could influence 
the efficiency of gene transfer? 
Can you offer some idea of the efficiency of gene 
transfer between liposomal versus adenoviral transfec- 
tion? Also, would you comment on the effect of temper- 
ature on adenoviral uptake and protein synthesis? It 
seems to me that at these lower temperatures, especially 
with adenovirus, the uptake into cells might be affected. 
and then at those lower temperatures, there might be an 
effect on protein synthesis. This has an impact on the use 
of strategies like this for transplantation as you start to 
look at more therapeutic sorts of vectors when you need 
to have efficient protein synthesis. 
In the in situ photograph, was that the sense construct 
control or was that just a histologic section? It looked like 
the histologlc section. I assume you have the sense control 
also and have some idea about background levels. 
This is an exciting strategy. It is clearly going to have an 
impact on the modification of transplant rejection and 
ischemia-reperfusion. 
Dr. Yano. Thank you. Dr. Kaiser. We did not assess 
variable doses of viral vector. However. I am sure that at 
higher doses of adenoviral vector, transfection will in- 
crease. In comparing the effect of the adenoviral and 
liposomal vectors, my impression is that the adenoviral 
vector is more effective. We did not assess variable 
temperature or time of exposure. 
Dr. Kaiser. You think the adenoviral vector was more 
effective than your liposomes? 
Dr. Yano. Yes, because if I used the adenoviral vector in 
my studies, not only endothelial cells but also smooth 
muscle cells were transfected. 
Dr. Casey W. Daggett (Durham, N.C.). What are your 
thoughts about he mechanisms of the loss of expression 
of the gene product? Als0, we have noticed in some of our 
models that a lot of the adenovirus i  taken up in the livers 
of these animals. Have you found similar results? 
Dr. Patterson. No. This was done as a preliminary series 
of experiments o see whether it was possible to achieve 
focal in vivo or ex vivo transfection. 
Dr. Alan P. Kypson (Durham, N.C.). Was there a 
reason that you chose a 20-minute xposure time? Have 
you evaluated the length of time that the adenoviral or the 
liposomal solution sits within the pulmonary artery seg- 
ment? Can you exPlain why you think there is a focal 
overexpression? Have you looked at any other segments 
of the pulmonary artery further distally? 
Dr. Patterson. No, we just examined the pulmonary 
artery segments hemselves. We did not conduct the same 
analysis of the pulmonary parenchyma. The administered 
dose is so small to that tiny segment of pulmonary artery 
that one would not expect o see any expression distally. 
Dr. Yano. In the in vivo experiments we chose 20 
minutes because we believed that would be the maximal 
tolerable time of warm ischemia. A 5-minute xposure 
time is not enOugh to ge t a good expression. 
Dr. Kypson. Do you think there was a reason for the 
50% mortality? 
Dr. Yano. In the in vivo experiments, the survival is 
approximately 50%. This is presumably due to the tech- 
nical difficulty including the cardiac puncture in addition 
to the effects of warm ischemic injury. 
Dr. Kaiser. Dr. Patterson, do you have any comments 
about he effect of temperature in the system? I think it is 
going to become important as you start looking at ways of 
expanding this model, and you still want to maintain the 
cold ischemia, especially if you are using a viral product. 
Dr. Patterson. We know that lungs can be preserved 
for several hours at 10 ° or 15°C and still have good 
graft function. In fact, some believe that better graft 
function can be obtained at modest hypothermia. Yet 
those temperatures are high enough to measure gene 
expression. Now, whether that is enough expression or 
efficient enough a transfer to get a functional effect, I
do not know. It seems that the higher the temperature 
up to room temperature, the better the expression. 
Dr. Jhingook Kim (Seoul, Korea). I want to ask about 
the strategy. If we apply the medication to the isograft, 
we can apply the medication directly. That is, if we want 
to have only increased angiogenicity, we can apply the 
vascular endothelial growth factor to the pulmonary 
artery directly. Otherwise, if we want to make a pro- 
longed expression of vascular endothelial growth factor, 
we should use the regular different ypes of the vector, 
such as retrovirus. Otherwise, if we use the adenoviral 
vector system, there will be just a brief expression of 
that kind of expected expression. Therefore I prefer to 
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use the retroviral vector system for the prolonged 
production. 
Our other method is to manage the endothelium in 
vitro and then make a patch with that endothelialized 
graft, the interposition graft, in the animal experiments. 
With that kind of strategy, we can make a prolonged 
expression of the expected gene and easily control the 
level of the expression. 
Dr. Aitorld. I believe the questioner wants to know why 
you want to use adenovirus versus retrovirus. 
Dr, Yano. In this study, retrovirus is not suitable for use 
because the endothelium is not a rapidly dividing cell 
population. Furthermore, short-term expression may be 
an advantage in this situation. 
Dr. Kaiser. I would echo that point. This strategy might be 
very useful if one is looking for short-term gene expression. 
Retroviruses create a significant number of problems, and 
perhaps adeno-associated virus may even be the better 
strategy. For that matter, liposomal gene transfers also 
could be given repeatedly without any sort of immune 
response. Many different strategies are available. 
Dr. Kim. If so, use of the end product of the gene, like 
the protein, would be an easier way to obtain that kind of 
effect. 
